IL17A and neoplasm: Secondly, LDH exerts an inflammatory action on tumor microenvironment, activating interleukin (IL)-23 and IL-17 and modulating the activity of arginase I. It inhibits CD8+ T lymphocytes and natural killer (NK) activation, allowing cancer cells to evade immune response [33].